

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 1

MIRA INFORM REPORT

Report No. :	542737
Report Date :	05.12.2018

IDENTIFICATION DETAILS

Name :	SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD.
Registered Office :	701, 7th Floor, Building A, Baofu Jewelry Industrial Park, No. 33 Bulan Road, Longgang District, Shenzhen, Guangdong Province 518112 Pr
Country :	China
Date of Incorporation :	23.05.2012
Unified Social Credit Code :	914403005967819271
Legal Form :	Limited Liabilities Company
Line of Business :	Subject registered business scope includes researching, developing, and manufacturing II & III items of medical electronic instrument, medical optical instruments, instruments & endoscopic equipment, medical ultrasonic instruments & related equipment, medical laser equipment, medical high frequency instrument, physical therapy and rehabilitation equipment, medical magnetic resonance equipment, medical X - ray equipment, medical ray equipment, medical equipment radionuclide, clinical test & analysis instrument, blood circulation and processing equipment, operation room, emergency rooms, clinics, medical equipment & apparatus, cooling temperature, refrigeration equipment and apparatus; II: medical X - ray equipment and components subsidiary, medical laboratory equipment and infrastructure, equipment and appliances, Department of Stomatology, ward care equipment and utensils, disinfection and sterilization equipment and apparatus, software; III: Medical ray protection device (II & III 6821 medical electronic equipment (medical monitor, heart medicine electrocardiogram machine); domestic trade; importing and exporting commodities and technology.
No. of Employees :	61

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 2

MIRA's Rating :	B
------------------------	----------

Credit Rating	Explanation	Rating Comments
B	Medium Risk	Business dealings permissible on a regular monitoring basis

Status :	Moderate
Payment Behaviour :	Unknown
Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating (30.06.2018)	Current Rating (30.09.2018)
China	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

CHINA - ECONOMIC OVERVIEW

Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2017 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.

In July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi (RMB) appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would resume a gradual appreciation. From 2013 until early 2015, the renminbi held steady against the dollar, but it depreciated 13% from mid-2015 until end-2016 amid strong capital outflows; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. In 2015, the People's Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF's special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.

The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China's population control policy known as the "one-child policy" - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.

The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 4

heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government's policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China's GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the "dominant" role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.

Source : CIA

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 5

COMPANY NAME & ADDRESS

COMPANY NAME	SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD.
CURRENT ADDRESS/ REGISTERED ADDRESS	701, 7TH FLOOR, BUILDING A, BAOFU JEWELRY INDUSTRIAL PARK, NO. 33 BULAN ROAD, LONGGANG DISTRICT, SHENZHEN, GUANGDONG PROVINCE 518112 PR CHINA
TEL. NO.	86 (0) 755-28260108
FAX NO.	86 (0) 755-85221277

EXECUTIVE SUMMARY

DATE OF REGISTRATION	: MAY 23, 2012
UNIFIED SOCIAL CREDIT CODE	: 914403005967819271
LEGAL FORM	: LIMITED LIABILITIES COMPANY
CHIEF EXECUTIVE	: CAO JIANBIAO (LEGAL REPRESENTATIVE)
REGISTERED CAPITAL	: CNY 50,000,000
STAFF	: 61
BUSINESS CATEGORY	: MANUFACTURING & TRADING
REVENUE	: N/A (AS OF DEC. 31, 2017)
EQUITIES	: N/A (AS OF DEC. 31, 2017)
WEBSITE	: www.hwatime.com
E-MAIL	: cjb@hwatime.com
PAYMENT	: UNKNOWN
MARKET CONDITION	: AVERAGE
FINANCIAL CONDITION	: N/A
OPERATIONAL TREND	: ORDINARY
GENERAL REPUTATION	: AVERAGE

Adopted abbreviations (as follows)

SC - Subject Company (the company inquired by you)

N/A – Not available

CNY – China Yuan Ren Min Bi

OPERATIONAL TREND & GENERAL REPUTATION

This section aims at indicating the relative positions of SC in respect of its operational trend & general reputation

Operational Trend:-
Upward
Steady

General Reputation:-
Excellent
Good

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Fairly Steady	Fairly Good
Ordinary	Average
Fair	Fair
Stagnant	Detrimental
Downward	Not known
Not known	Not yet be determined
Not yet be determined	

LEGAL STATUS & HISTORY

SC was established as a limited liabilities company of PRC with State Administration of Industry & Commerce (SAIC) under Unified Social Credit Code: 914403005967819271.

SC's registered capital: CNY 50,000,000

Registration Change Record:-

Date	Change of Contents	Before the change	After the change
2016-1-15	Registration No./ Unified Social Credit Code	440307106259101	914403005967819271

Current Co search indicates SC's shareholders & chief executives are as follows:-

Name of Shareholder (s)	% of Shareholding
Cao Jianbiao	98
Fan Shounian	2

SC's Chief Executives:-

Position	Name
Legal Representative, Chairman and General Manager	Cao Jianbiao
Supervisor	Fan Shounian

RECENT DEVELOPMENT

No recent development was found during our checks at present.

SHAREHOLDER CHART & BACKGROUND

Name	% of Shareholding
Cao Jianbiao	98
Fan Shounian	2

MANAGEMENT

Cao Jianbiao, Legal Representative, Chairman and General Manager

Gender: M
Qualification: University
Working experience (s):

At present, working in SC as legal representative, chairman and general manager
Also working in Jiangxi Huateng Medical Technology Co., Ltd., Shenzhen Huateng Medical Engineering Co., Ltd.
and Shenzhen Pairuikang Technology Co., Ltd. as legal representative

Supervisor

Fan Shounian

BUSINESS OPERATION

SC's registered business scope includes researching, developing, and manufacturing II & III items of medical electronic instrument, medical optical instruments, instruments & endoscopic equipment, medical ultrasonic instruments & related equipment, medical laser equipment, medical high frequency instrument, physical therapy and rehabilitation equipment, medical magnetic resonance equipment, medical X - ray equipment, medical ray equipment, medical equipment radionuclide, clinical test & analysis instrument, blood circulation and processing equipment, operation room, emergency rooms, clinics, medical equipment & apparatus, cooling temperature, refrigeration equipment and apparatus; II: medical X - ray equipment and components subsidiary, medical laboratory equipment and infrastructure, equipment and appliances, Department of Stomatology, ward care equipment and utensils, disinfection and sterilization equipment and apparatus, software; III: Medical ray protection device (II & III 6821 medical electronic equipment (medical monitor, heart medicine electrocardiogram machine); domestic trade; importing and exporting commodities and technology.

SC is mainly engaged in manufacturing and selling medical instrument and equipment.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 8

SC's products mainly include:
Patient Monitor
Engineer Equipment
Oxygen Generator



Trademarks:

华腾 Hwatime **HWATIME** 华腾

SC sources its materials 100% from domestic market. SC sells 60% of its products in domestic market, and 40% to overseas market.

The buying terms of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.

Staff & Office:

SC is known to have approx. 61 staff at present.

SC owns an area as its operating office and factory, but the detailed information is unknown.

RELATED COMPANY

SC is known to have the following subsidiaries at present,

Jiangxi Huateng Medical Technology Co., Ltd.
Unified Social Credit Code: 91360124MA35G1WW26
Date of Registration: December 25, 2015
Legal Form: Limited Liabilities Company
Registered Capital: CNY 2,000,000
Legal Representative: Cao Jianbiao

Shenzhen Huateng Medical Engineering Co., Ltd.
Unified Social Credit Code: 91440300094210331X
Date of Registration: April 15, 2014
Legal Form: Limited Liabilities Company
Registered Capital: CNY 300,000,000
Legal Representative: Cao Jianbiao

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SHENZHEN HWATIME BIOLOGICAL MEDICAL ELECTRONICS CO., LTD. - 542737

PAGE NO. : 9

Shenzhen Pairuikang Technology Co., Ltd.
Unified Social Credit Code: 91440300060255056J
Date of Registration: December 26, 2012
Legal Form: Limited Liabilities Company
Registered Capital: CNY 100,000
Legal Representative: Cao Jianbiao

PAYMENT

Overall payment appraisal:

Excellent Good Average Fair Poor Not yet be determined

The appraisal serves as a reference to reveal SC's payments habits and ability to pay. It is based on the 3 weighed factors: Trade payment experience (through current enquiry with SC's suppliers), our delinquent payment and our debt collection record concerning SC.

Trade payment experience: SC did not provide any name of trade/service suppliers and we have no other sources to conduct the enquiry at present.

Delinquent payment record: None in our database.

Debt collection record: No overdue amount owed by SC was placed to us for collection within the last 6 years.

BANKING

Basic Bank:

Agricultural Bank of China Longyuan Sub-branch

AC#: 41026300048888881

FINANCIALS

SC's financials are not filed in local SAIC, and SC also refused to release the details.

CONCLUSIONS

SC is considered small-sized in its line with 6 years history.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 70.35
UK Pound	1	INR 89.65
Euro	1	INR 80.07
CNY	1	INR 10.30

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	NIY
Report Prepared by :	TPT

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)